PLX
Protalix Biotherapeutics Inc
2.80$
+2.2%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +23.9% | -15.4% | -12.2% | -15.3% | -25.7% | +49.7% | +8.4% | -24.3% | +51.4% | -13.0% | +12.2% | |
| – | +31.1% | -16.3% | -12.8% | -15.4% | -38.7% | +71.6% | +10.7% | -27.2% | +55.8% | -14.1% | +11.0% | |
| – | +39.5% | -17.1% | -19.1% | -26.1% | -52.9% | +2.7% | +113.4% | -56.1% | +38.1% | -16.4% | -25.7% | |
| – | +39.5% | -17.1% | -19.1% | -26.1% | -52.9% | +116.6% | +1.1% | -43.1% | +100.9% | -21.8% | -13.1% | |
| – | +10.0% | -66.6% | +148.3% | +174.8% | -0.6% | -57.4% | +72.1% | +33.2% | +15.0% | -44.8% | +203.9% | |
| – | -13.5% | -9.1% | +49.3% | +9.4% | -4.8% | +60.4% | +37.2% | -6.4% | +13.3% | +11.5% | +21.1% | |
| – | -13.6% | -10.7% | -11.8% | -16.8% | -17.5% | +97.5% | -4.7% | -2.8% | +12.9% | -7.9% | +25.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -35.6% | +6.7% | +12.3% | +10.1% | +1.5% | -17.9% | -16.1% | -16.7% | -23.4% | -40.6% | +12.9% | |
| – | -57.1% | +489.3% | -65.6% | +11.4% | +58.5% | +115.2% | -61.6% | -2.3% | +40.4% | -43.7% | +3.5% | |
| – | -39.6% | +873.5% | -89.0% | -100.0% | – | +1,001.7% | -98.0% | -7.4% | +1,963.4% | -93.5% | -7.7% | |
| – | -8.1% | +10.4% | +87.7% | -30.7% | +24.6% | +11.2% | -3.3% | -16.1% | -26.3% | +4.9% | +16.0% | |
| – | +6.9% | -67.2% | +95.7% | +3.7% | +6.2% | -99.9% | +54,580.4% | +1.1% | – | – | – | |
| – | – | -191.6% | – | – | – | – | – | – | – | +28.7% | +11.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +2.2% | +6.8% | +29.3% | +12.2% | +0.8% | +96.4% | +51.4% | +9.8% | +70.0% | -1.7% | -3.1% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.